SEC Company Response from SELLAS Life Sciences Group, Inc. (SLS) (CIK 0001390478) (SLS) — Aug 4, 2016
SELLAS Life Sciences Group, Inc. (SLS) (CIK 0001390478)
Date: Aug. 4, 2016 · CIK: 0001390478 · Accession: 0001193125-16-671440
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-212674
Letter
VIA EDGAR Office of Insurance and Healthcare Registration Statement on Form S-3 Filed July 25, 2016 File No. 333-212674
Re: Galena Biopharma, Inc.
Dear Ms. Jaskot:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Galena Biopharma, Inc. (the “Company”) requests acceleration of the effective date of the above-referenced Registration Statement so that the same shall become effective as of 4:30 p.m., Washington, DC time, on August 5, 2016, or as soon thereafter as possible.
The Company hereby acknowledges that:
•
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Sincerely,
/s/ Mark W. Schwartz
Show Raw Text
CORRESP 1 filename1.htm CORRESP August 4, 2016 VIA EDGAR U.S. Securities and Exchange Commission Attn: Erin Jaskot and Dorrie Yale Office of Insurance and Healthcare 100 F Street NE Washington, DC 20549 Re: Galena Biopharma, Inc. Registration Statement on Form S-3 Filed July 25, 2016 File No. 333-212674 Dear Ms. Jaskot: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Galena Biopharma, Inc. (the “Company”) requests acceleration of the effective date of the above-referenced Registration Statement so that the same shall become effective as of 4:30 p.m., Washington, DC time, on August 5, 2016, or as soon thereafter as possible. The Company hereby acknowledges that: • should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; • the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and • the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Sincerely, /s/ Mark W. Schwartz Mark W. Schwartz, Ph.D. President and Chief Executive Officer